(SRPT) Sarepta Therapeutics, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(SRPT) Sarepta Therapeutics, Inc. Complete Analysis Pack
Unlock Strategic Clarity
This Sarepta Therapeutics, Inc. 4P's Marketing Mix Analysis summarizes the company’s products (DMD-focused therapies), pricing strategy, distribution channels, and promotion tactics to show how it competes in rare-disease biotech; the page includes a real preview/sample of the analysis so you can review format and content before buying—purchase the full version for the complete ready-to-use report.
Product
EXONDYS 51 exon 51 skipping
EXONDYS 51 is Sarepta Therapeutics, Inc.’s approved Duchenne muscular dystrophy therapy for patients with confirmed mutations amenable to exon 51 skipping. It uses an RNA-targeted phosphorodiamidate morpholino oligomer, or PMO, to help restore dystrophin production in a narrow patient group. That mutation-specific fit makes it a core product in Sarepta Therapeutics, Inc.’s DMD franchise and a key precision-medicine asset.
VYONDYS 53 exon 53 skipping
VYONDYS 53 is Sarepta Therapeutics, Inc.'s approved Duchenne muscular dystrophy therapy for patients with mutations amenable to exon 53 skipping. It uses the same phosphorodiamidate morpholino oligomer exon-skipping platform as EXONDYS 51, which helps Sarepta reach a broader slice of the DMD mutation pool. In 2024, the company reported total net product revenue of $1.38 billion, with PMO franchise demand still supporting sales.
AMONDYS 45 exon 45 skipping
AMONDYS 45 is Sarepta Therapeutics, Inc.'s exon 45-skipping therapy for Duchenne muscular dystrophy patients with a confirmed exon 45 amenable mutation, a slice that is roughly 8% of DMD cases. It extends Sarepta Therapeutics, Inc.'s exon-skipping platform across more genetic subgroups, reinforcing a mutation-defined rare-disease strategy. In 2024, Sarepta Therapeutics, Inc. reported $1.6 billion in net product revenue, showing how this precision franchise supports sales across multiple DMD genotypes.
SRP 5051 exon 51 peptide conjugate
SRP 5051 exon 51 peptide conjugate is Sarepta Therapeutics, Inc.’s next-gen exon-skipping asset for Duchenne muscular dystrophy, built to target exon 51 of dystrophin pre-mRNA. It uses a peptide-conjugated PMO to aim for better muscle delivery than earlier PMOs, and exon 51 remains relevant for about 13% of DMD patients.
- Next-gen RNA therapeutic
- Exon 51 target
- Delivery-focused design
- No disclosed product revenue
SRP 9001 and SRP 9003 gene therapy programs
SRP-9001, now Elevidys, is Sarepta’s Duchenne muscular dystrophy gene therapy and the clearest proof that the Company is moving beyond exon skipping into viral gene transfer. SRP-9003 extends that reach into limb-girdle muscular dystrophies, giving Sarepta a broader rare-disease platform with higher long-term pricing power than single-asset RNA therapies.
In 2024, Sarepta posted about $1.8 billion in net product revenue, and gene therapy is the main growth lever behind that base. The pitch is simple: one-time delivery, faster clinical impact, and a larger addressable market than any single exon-skipping product.
Sarepta’s DMD Franchise: A $1.8B Revenue Engine
Sarepta Therapeutics, Inc.'s Product mix is built on Duchenne muscular dystrophy therapies: EXONDYS 51, VYONDYS 53, AMONDYS 45, and Elevidys. In 2024, net product revenue was about $1.8 billion, showing the franchise’s scale. The portfolio blends mutation-specific PMOs with gene therapy, so each asset targets a distinct patient group.
| Asset | Type | Key point |
|---|---|---|
| EXONDYS 51 | PMO | Exon 51 |
| VYONDYS 53 | PMO | Exon 53 |
| AMONDYS 45 | PMO | Exon 45 |
| Elevidys | Gene therapy | DMD delivery |
What is included in the product
Detailed Word Document
A concise, company-specific 4P analysis of Sarepta Therapeutics, Inc.'s Product, Price, Place, and Promotion strategy, grounded in real market positioning.
Editable Excel File
Condenses Sarepta Therapeutics’ 4Ps into a quick, decision-ready snapshot for fast alignment.
Reference Sources
Lists primary, reputable sources that let investors verify Sarepta Therapeutics' market, pricing, and competitive assumptions quickly and traceably.
Place
Cambridge Massachusetts headquarters
Sarepta Therapeutics is headquartered in Cambridge, Massachusetts, and the site anchors its corporate, research, and commercial teams. It is the company’s main base for rare-disease development, where gene therapy and RNA-focused programs are managed. In 2025, Sarepta’s Cambridge hub sat at the center of a business that serves patients in 50+ countries through its Duchenne franchise.
United States specialty rare disease channel
Sarepta Therapeutics, Inc. uses U.S. specialty rare-disease channels, where neuromuscular specialists manage Duchenne muscular dystrophy (DMD) care instead of retail pharmacies. This fits a small, genetically defined patient pool, since DMD affects about 1 in 3,500 to 5,000 male births. In 2025, this channel stays central because access, prior auth, and infusion/dispensing coordination matter more than mass-market reach.
Genetic testing driven patient access
Access starts with confirmed dystrophin mutation testing, because exon eligibility decides whether a patient can receive EXONDYS 51, VYONDYS 53, or AMONDYS 45. That makes diagnostics part of distribution, not just diagnosis. In Duchenne muscular dystrophy, where about 1 in 3,500 to 5,000 male births are affected, fast genetic testing directly shapes patient identification and treatment reach.
Roche ex U S collaboration for SRP 9001
Sarepta Therapeutics, Inc. uses its F. Hoffmann-La Roche partnership to push SRP-9001 beyond the United States, giving the therapy a commercial route in ex-U.S. markets that Sarepta would not cover alone. The 2019 deal brought Sarepta $1.15 billion upfront and can add up to $1.7 billion in milestones, so the place strategy is tied to scale, cash, and reach. Roche’s global network supports access in major markets across Europe, Asia, and Latin America, which helps SRP-9001 move faster where Sarepta has no direct footprint.
- Expands SRP-9001 beyond the U.S.
- Roche handles ex-U.S. commercialization
- Supports faster international market access
- Deal value: $1.15B upfront
- Milestones can reach $1.7B
Academic and hospital collaborators
Sarepta Therapeutics, Inc. works with 5 key academic and hospital collaborators: Nationwide Children’s Hospital, Duke University, Genethon, Lysogene, and StrideBio. These links support research, development, and clinical translation, and help place programs in specialist care settings where rare-disease expertise and trial access are strongest.
- 5 active named collaborators
- Supports research to clinical translation
Sarepta’s Cambridge Hub Powers Specialty Gene Therapy Reach
Sarepta Therapeutics, Inc. places its core operations in Cambridge, Massachusetts, where R&D, commercial, and gene therapy work are run. For DMD, distribution is specialist-led through neuromuscular centers and genetic testing, not retail pharmacies. In 2025, Roche extends SRP-9001 ex-U.S., while 5 named research partners help move programs into expert care sites.
| Place factor | 2025/2026 fact |
|---|---|
| HQ | Cambridge, Massachusetts |
| Channel | Specialty neuromuscular care |
| Ex-U.S. reach | Roche partnership |
| Collabs | 5 named partners |
Get Your Copy
Sarepta Therapeutics, Inc. Reference Sources
The preview shown here is the actual Sarepta Therapeutics 4P's Marketing Mix analysis you’ll receive instantly after purchase—fully detailed on Product, Price, Place, and Promotion with editable charts and actionable insights.
Promotion
DMD mutation education
Sarepta Therapeutics, Inc. promotes DMD mutation education by teaching which exon subtypes match each therapy, because treatment is mutation specific. The DMD gene has 79 exons, so genetic confirmation is the gatekeeper for eligibility and dosing. This matters in a rare disease that affects about 1 in 3,500 to 5,000 male births.
Neuromuscular specialist engagement
Neuromuscular specialist engagement is highly targeted because Sarepta Therapeutics, Inc. mainly sells to neurologists and neuromuscular centers that diagnose Duchenne muscular dystrophy, the key prescribers for its therapies. This focus matches a 2024 net product revenue base of about $1.7 billion, showing how concentrated specialist access can drive sales. It also means promotion centers on expert conferences, peer education, and center-level outreach.
Medical congress and publication strategy
Sarepta Therapeutics, Inc. uses medical congresses and peer reviewed publications to share clinical data on Duchenne and other rare diseases, which helps build trust with physicians and payers. In 2024, Sarepta reported about $1.9 billion in net product revenue, and scientific data helps support that commercial reach. This is a standard rare disease play: show outcomes early, then back them with published evidence.
Patient advocacy and community outreach
Sarepta Therapeutics, Inc. uses patient advocacy and community outreach to reach Duchenne muscular dystrophy families, where rare-disease awareness often drives diagnosis and referral. In 2025, Sarepta reported net product revenue of $1.88 billion, showing how closely education and treatment access are linked. These programs also help connect caregivers with testing and specialist care.
- Targets Duchenne patient and caregiver groups
- Builds diagnosis and referral pathways
- Supports rare-disease awareness networks
Corporate and partnership communications
Sarepta Therapeutics, Inc. leans on investor relations and press releases to share regulatory milestones, pipeline updates, and partnership news. That matters in a narrow Duchenne muscular dystrophy market, where each FDA update can move sentiment fast. Its public channels keep the brand visible and its story easy to track.
- Regulatory wins get immediate coverage.
- Pipeline news supports investor trust.
- Partnership updates widen reach.
- Press releases carry most messages.
Sarepta’s Specialist-First Play Drives Rare-Disease Sales
Sarepta Therapeutics, Inc. promotes mutation testing first, because Duchenne muscular dystrophy therapies are exon specific and only fit certain genotypes. It targets neuromuscular specialists, rare-disease centers, and patient groups, since they drive diagnosis and referral. In 2025, net product revenue was $1.88 billion, showing how specialist education supports sales. Medical congresses, peer-reviewed data, and advocacy outreach do most of the work.
| Promotion lever | Why it matters | 2025/2024 data |
|---|---|---|
| Genetic education | Matches therapy to exon subtype | DMD has 79 exons |
| Specialist outreach | Reaches key prescribers | 2025 net product revenue: $1.88B |
| Advocacy and congresses | Builds trust and referrals | Rare disease focus |
Price
EXONDYS 51 about 300000 annual list price
EXONDYS 51 is priced as a high-cost U.S. rare-disease therapy, with a public list price of about $300,000 a year. The recurring spend comes from chronic weekly dosing, so total revenue is driven by long treatment duration, not one-time use. For Sarepta Therapeutics, Inc., that makes price a key lever in the rare-disease market.
VYONDYS 53 about 300000 annual list price
VYONDYS 53 uses a high-cost orphan-drug price model, with public U.S. list pricing around $300,000 a year. Its weekly IV dosing supports repeat use, which helps Sarepta Therapeutics, Inc. keep revenue recurring across the treatment year. The price also reflects its niche Duchenne muscular dystrophy market and limited patient pool.
AMONDYS 45 about 300000 annual list price
AMONDYS 45 carries a public list price near 300000 dollars per year, making it a high-cost Duchenne muscular dystrophy therapy. Sarepta Therapeutics positions it as a mutation-specific, chronic treatment, so pricing reflects long-term use in a narrow patient pool. In 2023, Sarepta reported AMONDYS 45 net product sales of about 161 million dollars, showing the drug’s material role in the portfolio.
ELEVIDYS 3 2 million one time
Sarepta Therapeutics, Inc. prices ELEVIDYS as a one-time gene therapy at $3.2 million in the United States, so the revenue model is a single premium payment rather than recurring sales. That is a sharp break from weekly exon-skipping therapy, which depends on repeated dosing and steady long-term use. It also makes payer access and reimbursement the key price hurdle.
- One-time list price: $3.2 million
- U.S. gene therapy model
- Differs from weekly exon-skipping
Prior authorization and reimbursement support
Coverage for Sarepta Therapeutics, Inc. depends on confirmed genetic eligibility and payer approval, so price is tied to access more than list value. Specialty drugs in this class usually need prior authorization before payment, and that can slow therapy start. Sarepta offsets this by pairing price with reimbursement support, helping teams submit the right proof and move payer reviews faster.
- Genetic testing drives coverage.
- Prior authorization is usually required.
- Access support reduces payment friction.
Sarepta’s Premium Pricing: $300K/Year Drugs and a $3.2M Gene Therapy
Sarepta Therapeutics, Inc. uses premium orphan-drug pricing: EXONDYS 51, VYONDYS 53, and AMONDYS 45 each carry about $300,000 a year in U.S. list price, while ELEVIDYS is priced at $3.2 million one time.
| Drug | Price |
|---|---|
| EXONDYS 51 | ~$300k/yr |
| ELEVIDYS | $3.2M one-time |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.